London stock exchange
Stocks and Finance

Novartis

Novartis 10/05/2012

05:39 : New data among 200 Lucentis® abstracts at ARVO show low number of injection - NOVARTIS FINANCE S.A. / New data among 200 Lucentis® abstracts at ARVO show low number of injections with Novartis drug required to achieve and maintain vision gains over 3 years in AMD and DME patients . Processed ...

Novartis 07/05/2012

22:13 : Novartis drug pasireotide LAR shows superior efficacy compared to Sandostat - NOVARTIS FINANCE S.A. / Novartis drug pasireotide LAR shows superior efficacy compared to Sandostatin® LAR® in Phase III trial of patients with acromegaly . Processed and transmitted by Thomson Reuters ...
06:00 : Novartis: Pasireotide Works Well In Acromegaly Trial - By Marta Falconi Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- An experimental drug by Novartis (NVS) for the treatment of a rare endocrine disorder is working better than the standard of care in a late-stage clinical trial, the company ...

Novartis 26/04/2012

22:00 : Novartis drug Afinitor® approved by FDA as first medication to treat patien - NOVARTIS FINANCE S.A. / Novartis drug Afinitor® approved by FDA as first medication to treat patients with non-cancerous kidney tumors associated with TSC . Processed and transmitted by Thomson Reuters ...

Novartis 24/04/2012

23:19 : UK Health Body Approves Novartis's Tasigna For CML - LONDON -(Dow Jones)- The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss ...
15:16 : Suing the NHS over cheap blindness drugs is a risky business, Novartis ... - The big pharma company may regret its attempt to stop the use of Avastin instead of a more expensive drug to prevent blindnessJohn le Carré will love this one. One of the world's leading drug companies, Switzerland-based Novartis, is going ...
Source : guardian-co-uk
06:33 : Pharmaceuticals and Alcon performed strongly in the first quarter; overall - NOVARTIS FINANCE S.A. / Pharmaceuticals and Alcon performed strongly in the first quarter; overall Group results impacted by expected challenges . Processed and transmitted by Thomson Reuters ONE. The issuer is solely ...

Novartis 20/04/2012

12:02 : Novartis updates US label on Gilenya® following discussions with the FDA - Novartis International AG / Novartis updates US label on Gilenya® following discussions with the FDA . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content ...
11:39 : European regulators back Novartis MS drug - European regulators have endorsed the continued use of Novartis's multiple sclerosis pill Gilenya, one of the Swiss firm's top new drug hopes, but said today the drug needed to carry stronger warnings on heart risks.
Source : irishtimes-com
10:29 : EU supports Novartis MS pill with stronger warning - LONDON (Reuters) - European regulators endorsed the continued use of Novartis AG's multiple sclerosis pill Gilenya, one of the Swiss firm's top new drug hopes, but said on Friday the drug needed to carry stronger warnings on heart risks.
Source : reuters-com

Novartis 19/04/2012

20:17 : Novartis announces Aliskiren will continue to be available to appropriate ... - NOVARTIS FINANCE S.A. / Novartis announces Aliskiren will continue to be available to appropriate patients, as FDA interim assessment is concluded; product information updated . Processed and transmitted by Thomson Reuters|Thomson ...
13:10 : Novartis: Experimental Hepatitis C Drug Development On Hold - ZURICH -(Dow Jones)- Novartis AG (NVS) said Thursday the development program of an experimental drug for the treatment of Hepatitis C has been placed on hold by U.S. regulators after the death of a patient, which may be linked the drug. ...

Novartis 14/04/2012

04:55 : Novartis unsure on MS drug link to case - SWISS drug maker Novartis said it's still not sure whether its new multiple sclerosis (MS) treatment contributed to a patient on the drug contracting a potentially deadly brain infection. The patient has been taking Gilenya, a drug approved ...
Source : independent-ie

Novartis 13/04/2012

10:56 : UPDATE: Novartis MS Pill Gilenya Patient Gets Rare Brain Disease - -- Development comes as Gilenya's safety is under scrutiny by European regulators -- Patient had been previously treated with Elan and Biogen's MS drug Tysabri -- Analysts say case should be taken seriously as adds to Gilenya safety concerns ...
09:48 : Novartis: MS Pill Gilenya Patient Develops Rare Brain Disease - ZURICH -(Dow Jones)- Novartis AG (NVS) Friday said a patient treated with its multiple-sclerosis pill Gilenya has been diagnosed with a rare and often fatal brain disease. The Swiss drug maker said the patient had been previously treated ...

Novartis 28/03/2012

17:24 : Novartis launches the Cancer Cell Line Encyclopedia (CCLE) to catalogue ... - Novartis International AG / Novartis launches the Cancer Cell Line Encyclopedia (CCLE) to catalogue world's cancer cell lines . Processed and transmitted by Thomson Reuters ONE. The issuer is solely ...

Novartis 27/03/2012

20:51 : Study in JAMA reports significant survival benefit in certain GIST patients - Novartis International AG / Study in JAMA reports significant survival benefit in certain GIST patients taking Novartis drug Glivec® for three years after surgery . Processed and transmitted by Thomson Reuters|Thomson ...

Novartis 07/03/2012

23:05 : Data in NEJM shows Novartis drug Signifor® is first therapy to provide ... - Novartis International AG / Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushing's disease patients in Phase III study . Processed and transmitted by Thomson Reuters|Thomson ...

Novartis 29/02/2012

22:34 : Brian McNamara Named Division Head, Novartis OTC - NOVARTIS FINANCE S.A. / Brian McNamara Named Division Head, Novartis OTC . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. ...
22:34 : Two Phase III studies of Novartis drug INC424 published in NEJM show signif - Novartis International AG / Two Phase III studies of Novartis drug INC424 published in NEJM show significant clinical benefit for patients with myelofibrosis . Processed and transmitted by Thomson Reuters ...

Novartis 23/02/2012

12:31 : Shareholders approve all proposed resolutions of Novartis Board of Director - NOVARTIS FINANCE S.A. / Shareholders approve all proposed resolutions of Novartis Board of Directors . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content ...

Novartis 21/02/2012

18:54 : Portfolio company Enanta enters into strategic collaboration with Novartis - Private Equity Holding AG / Portfolio company Enanta enters into strategic collaboration with Novartis . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. ...

Novartis 17/02/2012

10:31 : Novartis to revise product information in the European Union for high ... - NOVARTIS FINANCE S.A. / Novartis to revise product information in the European Union for high blood pressure drug Rasilez® following assessment by CHMP . Processed and transmitted by Thomson Reuters ...

Novartis 16/02/2012

01:21 : Apricus Bioscience's Wholly-Owned Subsidiary NexMed (USA) Signs Exclusive ... - SAN DIEGO, 2012-02-16 01:19 CET (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that its wholly-owned subsidiary NexMed(USA), Inc. has signed with Sandoz, a division ...

Novartis 07/02/2012

22:08 : Pivotal study published in JAMA confirms potential of Novartis candidate ... - NOVARTIS FINANCE S.A. / Pivotal study published in JAMA confirms potential of Novartis candidate vaccine Bexsero® to help protect infants against devastating meningococcal serogroup B disease . Processed and transmitted ...

Novartis 02/02/2012

15:10 : Shareholder group slams Novartis over chairman pay - ZURICH, Feb 2 (Reuters) - Shareholder group Ethos said Novartis investors should vote against re-electing board members in charge of allotting bonus pay to the Swiss drugmaker's chairman, Daniel Vasella.
Source : reuters-com

Novartis 30/01/2012

11:43 : Novartis extends commitment to help achieve final elimination of leprosy - NOVARTIS FINANCE S.A. / Novartis extends commitment to help achieve final elimination of leprosy . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content ...

Novartis 25/01/2012

06:14 : Novartis delivers strong underlying financial performance in 2011, expects - NOVARTIS FINANCE S.A. / Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011 . Processed and transmitted by Thomson Reuters ONE. The issuer is ...

Novartis 20/01/2012

17:22 : Europe shares up for 5th week on economic optimism - European shares notched up a fifth straight week of gains, as the outlook for the global economy improved and on optimism Greece would avoid a messy default, though Novartis led a slight reversal on Friday amid doubts about ...
Source : ibtimes-co-uk
15:01 : CHMP recommends EU approval to update Novartis drug Glivec® label to includ - Novartis International AG / CHMP recommends EU approval to update Novartis drug Glivec® label to include three year treatment for GIST patients after surgery . Processed and transmitted by Thomson Reuters ...
actualidad Novartis -


Copyright © 2009 Finaperf.com - Bourse - Börse - Day trading - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts